All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Dabrafenib/Trametinib Combo Receives Breakthrough Designation for NSCLC

July 23rd 2015

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib as a potential treatment for patients with BRAFV600E-mutant non-small cell lung cancer.

Failure to Follow Weight-Based Chemo Guidelines Lowers Survival in Ovarian Cancer

July 23rd 2015

Women with ovarian cancer who experienced an average dose reduction of ≤85% had a 35% higher mortality risk than those who received normal dosing.

Selumetinib Misses Endpoint in Phase III Uveal Melanoma Study

July 22nd 2015

Treatment with the combination of selumetinib and dacarbazine failed to improve progression-free survival compared with dacarbazine alone in patients with metastatic uveal melanoma.

Progress in HER2-Positive Breast Cancer Comes With Successes and Setbacks

July 22nd 2015

Mohammad Jahanzeb, MD, discusses impactful studies and other key issues in HER2-positive breast cancer.

European Commission Approves Pembrolizumab for Advanced Melanoma

July 22nd 2015

The European Commission has approved the PD-1 inhibitor pembrolizumab as a treatment for adult patients with unresectable or metastatic melanoma in the first-line and previously treated settings.

Court Clears First US Biosimilar for Future Marketing

July 21st 2015

An appellate court ruled that the FDA-approved biosimilar Zarxio can be marketed in the United States after September 2, 2015.

Efforts Continue to Refine Neoadjuvant HER2+ Breast Cancer Care

July 21st 2015

Douglas Yee, MD, explains current treatment options and ongoing research aimed at optimizing neoadjuvant therapy for HER2-positive breast cancer.

Nivolumab Gains European Approval for Squamous NSCLC

July 20th 2015

The European Commission has approved nivolumab as a treatment for patients with locally advanced or metastatic squamous non–small cell lung cancer following prior chemotherapy.

Nivolumab Improves Survival in Phase III RCC Trial

July 20th 2015

The phase III CheckMate-025 trial has been halted after an independent panel determined that nivolumab improved overall survival versus everolimus in patients with advanced renal cell carcinoma.

Second-Line Cabozantinib Improves OS, PFS in mRCC

July 20th 2015

Treatment with cabozantinib improved progression-free survival and overall survival compared with everolimus in pretreated patients with metastatic renal cell carcinoma.

Innovative Use of Technology for Palliative Care

July 19th 2015

Innovative models for palliative care delivery and primary palliative care training are springing up to address the demand–capacity mismatch.

Coleman Explains New Biomarker for PARP Inhibitors in Ovarian Cancer

July 17th 2015

Robert Coleman, MD, discusses a potential new biomarker for PARP inhibition in ovarian cancer that was examined in the ARIEL2 trial.

FDA Grants Peptide Vaccine Orphan Status for Ovarian Cancer

July 17th 2015

The FDA has granted an orphan drug designation to the immunotherapy DPX-Survivac as a treatment for women with ovarian cancer.

Blinatumomab Effective in Phase II Ph+ ALL Study

July 17th 2015

Monotherapy with blinatumomab has demonstrated promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia.

MM-398 and Other Novel Agents Improve Outlook in Pancreatic Cancer

July 16th 2015

Philip Philip, MD, PhD, discusses how MM-398 and other emerging therapies are offering new hope to patients with pancreatic cancer.

Everolimus Activity Linked With PIK3CA/PTEN Status in HER2-Positive Breast Cancer

July 16th 2015

PIK3CA mutations and low/no expression of PTEN correlated with an extension in progression-free survival for patients with metastatic HER2-positive breast cancer treated with the combination of everolimus, trastuzumab, and paclitaxel.

OncLive Adds UW Carbone Cancer Center to Its Roster of Strategic Alliance Partners

July 16th 2015

Focus will be on Wisconsin Center's innovative research centers and impact on local communities.

Van Cutsem Discusses Regorafenib, Emergence of Precision Medicine in mCRC

July 16th 2015

Eric Van Cutsem, MD, PhD, discusses results from the phase IIIb CONSIGN study and the continuing advance of precision medicine in colorectal cancer.

PD-1 Blockade Effective in Mismatch Repair-Deficient CRC

July 15th 2015

James J. Lee, MD, PhD, discusses research into mismatch repair deficiency as a biomarker for PD-1 inhibition in colorectal cancer.

FDA Approval Sought for Ixazomib in Relapsed/Refractory Myeloma

July 14th 2015

A new drug application has been submitted for the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma

x